Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study.

Another phase 2 randomised, double-blind, placebo-controlled trial of the neurokinin 1 receptor antagonist, serlopitant, included itch reduction as a primary endpoint in different types of EB; although not reaching statistical significance, results showed a trend for greater itch score reduction in the treatment arm [ 17 ].

also in 53,322 other papers